{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:42:10Z","timestamp":1773276130833,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25456-9","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:29:41Z","timestamp":1763987381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2"],"prefix":"10.1038","volume":"15","author":[{"given":"Ali","family":"Darvishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajabali","family":"Daroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Dehghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gita","family":"Shafiee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"1","key":"25456_CR1","doi-asserted-by":"publisher","first-page":"e70029","DOI":"10.1002\/dmrr.70029","volume":"41","author":"S Goyal","year":"2025","unstructured":"Goyal, S. & Vanita, V. The rise of type 2 diabetes in children and adolescents: an emerging pandemic. Diab.\/Metab. Res. Rev. 41 (1), e70029 (2025).","journal-title":"Diab.\/Metab. Res. Rev."},{"key":"25456_CR2","volume-title":"IDF DIABETES ATLAS","author":"DJ Magliano","year":"2021","unstructured":"Magliano, D. J., Boyko, E. J. IDF Diabetes Atlas 10th edition scientific committee (International Diabetes Federation, Brussels, 2021)."},{"key":"25456_CR3","unstructured":"World Health, O. Global Report on Diabetes (World Health Organization, 2016)."},{"key":"25456_CR4","doi-asserted-by":"crossref","unstructured":"Al-Worafi, Y. M. Epidemiology and Burden of Diabetes Mellitus in Developing Countries, in Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research, Y.M. Al-Worafi, Editor. Springer International Publishing: Cham. pp. 1\u201327. (2023).","DOI":"10.1007\/978-3-030-74786-2_334-1"},{"issue":"9","key":"25456_CR5","first-page":"e45835","volume":"15","author":"M Zakir","year":"2023","unstructured":"Zakir, M. et al. Cardiovascular complications of diabetes: from microvascular to macrovascular pathways. Cureus 15 (9), e45835 (2023).","journal-title":"Cureus"},{"issue":"1","key":"25456_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12961-022-00886-3","volume":"20","author":"T Rahman","year":"2022","unstructured":"Rahman, T., Gasbarro, D. & Alam, K. Financial risk protection from out-of-pocket health spending in low-and middle-income countries: a scoping review of the literature. Health Res. Policy Syst. 20 (1), 83 (2022).","journal-title":"Health Res. Policy Syst."},{"issue":"1","key":"25456_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12889-024-21247-5","volume":"25","author":"A Mohammadi","year":"2025","unstructured":"Mohammadi, A. et al. Economic burden of type 2 diabetes in Iran in 2022. BMC Public. Health. 25 (1), 35 (2025).","journal-title":"BMC Public. Health"},{"issue":"Supplement_1","key":"25456_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc23-Sint","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed, N. A. et al. Introduction and methodology: standards of care in Diabetes\u20142023. Diabetes Care. 46 (Supplement_1), S1\u2013S4 (2022).","journal-title":"Diabetes Care"},{"issue":"11","key":"25456_CR9","first-page":"2563","volume":"11","author":"N Jahanmehr","year":"2022","unstructured":"Jahanmehr, N. et al. The projection of iran\u2019s healthcare expenditures by 2030: evidence of a Time-Series analysis. Int. J. Health Policy Manag. 11 (11), 2563\u20132573 (2022).","journal-title":"Int. J. Health Policy Manag"},{"key":"25456_CR10","unstructured":"European Observatory Health Policy Series, in Health system efficiency: How to make measurement matter for policy and management, J. Cylus, I. Papanicolas, and P.C. Smith, Editors. European Observatory on Health Systems and Policies \u00a9 World Health Organization 2016 (acting as the host organization for, and secretariat of, the European Observatory on Health Systems and Policies). Copenhagen (Denmark). (2016)."},{"issue":"4","key":"25456_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3111\/13696998.2012.670677","volume":"15","author":"AL Guillermin","year":"2012","unstructured":"Guillermin, A. L. et al. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or Pioglitazone for the treatment of type 2 diabetes patients in the united States. J. Med. Econ. 15 (4), 654\u2013663 (2012).","journal-title":"J. Med. Econ."},{"issue":"11","key":"25456_CR12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s40273-023-01268-5","volume":"41","author":"HVB Laursen","year":"2023","unstructured":"Laursen, H. V. B. et al. A systematic review of Cost-Effectiveness studies of newer Non-Insulin antidiabetic drugs: trends in Decision-Analytical models for modelling of type 2 diabetes mellitus. Pharmacoeconomics 41 (11), 1469\u20131514 (2023).","journal-title":"Pharmacoeconomics"},{"issue":"21","key":"25456_CR13","doi-asserted-by":"publisher","first-page":"e034531","DOI":"10.1161\/JAHA.123.034531","volume":"13","author":"F Yuan","year":"2024","unstructured":"Yuan, F., Spence, J. D. & Tarride, J. E. Cost-Utility analysis of Low-Dose Pioglitazone in a population with prediabetes and a history of stroke or transient ischemic attack. J. Am. Heart Assoc. 13 (21), e034531 (2024).","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"25456_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes, A. J. et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year united Kingdom prospective diabetes study: UKPDS 82. Diabetologia 56 (9), 1925\u20131933 (2013).","journal-title":"Diabetologia"},{"issue":"1","key":"25456_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40200-022-01149-2","volume":"22","author":"G Shafiee","year":"2023","unstructured":"Shafiee, G. et al. Management goal achievements of diabetes care in iran: study profile and main findings of diacare survey. J. Diabetes Metab. Disord. 22 (1), 355\u2013366 (2023).","journal-title":"J. Diabetes Metab. Disord"},{"issue":"9","key":"25456_CR16","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas, A. et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes. Metab. 23 (9), 2116\u20132124 (2021).","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"25456_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas, A. et al. Comparative effectiveness of Glucose-Lowering drugs for type 2 diabetes: A systematic review and network Meta-analysis. Ann. Intern. Med. 173 (4), 278\u2013286 (2020).","journal-title":"Ann. Intern. Med."},{"key":"25456_CR18","unstructured":"Iran, S. C. Consumer Price Index \u2013 Health Sector. (2023)."},{"issue":"1","key":"25456_CR19","doi-asserted-by":"publisher","first-page":"e117711","DOI":"10.5812\/jhealthscope.117711","volume":"11","author":"M Shirvani Shiri","year":"2022","unstructured":"Shirvani Shiri, M. et al. Hospitalization expenses and influencing factors for inpatients with ischemic heart disease in iran: A retrospective study. Health Scope. 11 (1), e117711 (2022).","journal-title":"Health Scope"},{"issue":"12","key":"25456_CR20","doi-asserted-by":"publisher","first-page":"e067573","DOI":"10.1136\/bmjopen-2022-067573","volume":"12","author":"Z Kazemi","year":"2022","unstructured":"Kazemi, Z. et al. Estimation and predictors of direct hospitalisation expenses and in-hospital mortality for patients who had a stroke in a low-middle income country: evidence from a nationwide cross-sectional study in Iranian hospitals. BMJ Open. 12 (12), e067573 (2022).","journal-title":"BMJ Open."},{"key":"25456_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.vhri.2020.04.004","volume":"24","author":"MS Movahed","year":"2021","unstructured":"Movahed, M. S. et al. Economic burden of stroke in iran: A Population-Based study. Value Health Reg. Issues. 24, 77\u201381 (2021).","journal-title":"Value Health Reg. Issues"},{"issue":"1","key":"25456_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13561-022-00377-9","volume":"12","author":"RS Shahtaheri","year":"2022","unstructured":"Shahtaheri, R. S. et al. Long-term cost-effectiveness of quality of diabetes care; experiences from private and public diabetes centers in Iran. Health Econ. Rev. 12 (1), 44 (2022).","journal-title":"Health Econ. Rev."},{"issue":"10","key":"25456_CR23","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","volume":"40","author":"V Jha","year":"2023","unstructured":"Jha, V. et al. Global economic burden associated with chronic kidney disease: A pragmatic review of medical costs for the inside CKD research programme. Adv. Ther. 40 (10), 4405\u20134420 (2023).","journal-title":"Adv. Ther."},{"issue":"8","key":"25456_CR24","doi-asserted-by":"publisher","first-page":"e44526","DOI":"10.1371\/journal.pone.0044526","volume":"7","author":"M Javanbakht","year":"2012","unstructured":"Javanbakht, M. et al. Health related quality of life in patients with type 2 diabetes mellitus in iran: a National survey. PLoS One. 7 (8), e44526 (2012).","journal-title":"PLoS One"},{"key":"25456_CR25","unstructured":"Bank, W. GDP per capita, PPP (current international $) - Iran, Islamic Rep."},{"key":"25456_CR26","unstructured":"Bank, W. PPP conversion factor, GDP (LCU per international $) - Iran, Islamic Rep.; Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP?locations=IR"},{"key":"25456_CR27","doi-asserted-by":"crossref","unstructured":"Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations Vol. 7, p. 23814683211061097 (MDM Policy & Practice, 2022). 1.","DOI":"10.1177\/23814683211061097"},{"issue":"4","key":"25456_CR28","first-page":"443","volume":"11","author":"L Zarei","year":"2022","unstructured":"Zarei, L. et al. Affordability of medication therapy in diabetic patients: A Scenario-Based assessment in iran\u2019s health system context. Int. J. Health Policy Manag. 11 (4), 443\u2013452 (2022).","journal-title":"Int. J. Health Policy Manag"},{"issue":"1","key":"25456_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1524-4733.2008.00403.x","volume":"12","author":"WJ Valentine","year":"2009","unstructured":"Valentine, W. J. et al. Long-term cost-effectiveness of Pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on proactive. Value Health. 12 (1), 1\u20139 (2009).","journal-title":"Value Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25456-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25456-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25456-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:29:46Z","timestamp":1763987386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25456-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25456"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25456-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All study protocols approved by the Ethics Committee of Tehran university of medical sciences (IR.TUMS.EMRI.REC.1401.097).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"41536"}}